CTSD and cancer: Nevertheless, one could therapeutically exploit the CTSD deficiency-induced phenotype by applying a two-hit synthetic lethal strategy as suggested by Wang et al.46, with initial induction of a quiescent cancer cell phenotype by CTSD inactivation, followed by specific killing with senolytic agents.